Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00976989 · BASELINE

Baseline characteristics

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer · Source last updated 2017-02-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      73
    2. group Id
      BG001
      value
      75
    3. group Id
      BG002
      value
      77
    4. group Id
      BG003
      value
      225
    units
    Participants
groups
  1. description
    5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
    id
    BG000
    title
    T+P Concomitant Anthracycline-based Chemotherapy
  2. description
    FEC every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
    id
    BG001
    title
    T+P Sequential Anthracycline-based Chemotherapy
  3. description
    Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
    id
    BG002
    title
    T+P Concomitant Non-Anthracycline Chemotherapy
  4. description
    Total of all reporting groups
    id
    BG003
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.41
          value
          49.6
        2. group Id
          BG001
          spread
          10.70
          value
          50.5
        3. group Id
          BG002
          spread
          10.58
          value
          50.6
        4. group Id
          BG003
          spread
          10.86
          value
          50.6
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          73
        2. group Id
          BG001
          value
          75
        3. group Id
          BG002
          value
          77
        4. group Id
          BG003
          value
          225
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        4. group Id
          BG003
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Gender
    unit Of Measure
    Participants
population Description
Safety population included all participants who were randomized and received study drug.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      73
    2. group Id
      BG001
      value
      75
    3. group Id
      BG002
      value
      77
    4. group Id
      BG003
      value
      225
    units
    Participants
groups
  1. description
    5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
    id
    BG000
    title
    T+P Concomitant Anthracycline-based Chemotherapy
  2. description
    FEC every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
    id
    BG001
    title
    T+P Sequential Anthracycline-based Chemotherapy
  3. description
    Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
    id
    BG002
    title
    T+P Concomitant Non-Anthracycline Chemotherapy
  4. description
    Total of all reporting groups
    id
    BG003
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.41
          value
          49.6
        2. group Id
          BG001
          spread
          10.70
          value
          50.5
        3. group Id
          BG002
          spread
          10.58
          value
          50.6
        4. group Id
          BG003
          spread
          10.86
          value
          50.6
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          73
        2. group Id
          BG001
          value
          75
        3. group Id
          BG002
          value
          77
        4. group Id
          BG003
          value
          225
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        4. group Id
          BG003
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Gender
    unit Of Measure
    Participants
population Description
Safety population included all participants who were randomized and received study drug.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice